SCHEMBL2977895

SCHEMBL2977895

CC(C)(C)OC(=O)N1CC2CC(C(=O)Cl)CC2C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.64
HPGD P15428 1/20 0.43
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RECQL P46063 1/20 0.41
JAK1 P23458 2/20 0.41
JAK2 O60674 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX2 P34913 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GPR119 Q8TDV5 2/20 0.38
PREP P48147 2/20 0.38
EPHX1 P07099 1/20 0.38
PTPN2 P17706 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994691 0.87 NR1H2 (0.56) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL25010845 0.87 NR1H2 (0.74) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL10242790 0.87 NR1H2 (0.74) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL4224986 0.87 NR1H2 (0.74) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL19456156 0.87 NR1H2 (0.74) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL16042198 0.86 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL2978266 0.86 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL28914482 0.86 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL16962257 0.86 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL22629774 0.86 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198296-B2 Sub-type selective azabicycloalkane derivatives TARGACEPT, INC. (US) 2012-06-12 US disclosed
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2010-07-08 US disclosed
EP-2139857-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES Targacept Inc. (US) 2010-01-06 EP disclosed
WO-2008121686-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES CHRNB2, CHRNB4, CHRNA4 NR1H2 583/4885HPGD 2045/4885USP2 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.